A Pittsburgh-designed medical device has received federal  approval for emergency use in the fight against COVID-19.

ALung Technologies Inc., a medical technology startup on the South Side, created its signature Hemolung more than 13 years ago. The device, which removes carbon dioxide from the bloodstream to outside the body, can be used in conjunction with or instead of a mechanical ventilator, or with non-invasive ventilation treatments such as oxygenation by nasal catheter.

The Hemolung’s approval is very good news for patients suffering with COVID-19. The mortality rate for patients who require ventilators is in excess of 90%, according to  early data. This may be due in part to the fact that a ventilator often increases inflammation in the lungs as it forces patients to breathe, and some doctors have moved away from using mechanical ventilators where possible in treating COVID-19 patients.

The Hemolung is currently in the midst of a pair of significant clinical trials in 36 hospitals in the U.S., including Allegheny General Hospital on the North Side, and doctors at the trial hospitals have begun using the Hemolung to treat patients who have been infected with the coronavirus that triggers COVID-19. The company currently makes eight to 10 machines per month, but is poised to increase that number.

Advertise with us

Peter DeComo, CEO of ALung and former director of respiratory services at Shadyside Hospital, said he is encouraged by doctors’ reports. He said he couldn’t say how many patients have been treated with the device, citing privacy reasons.

“Related to outcomes, I can tell you the physicians using the device are providing very positive feedback,” he said. “One told us recently that the only reason a patient is alive is because of the Hemolung.”

Mr. DeComo said hospitals not involved in the trials are beginning to request and use the Hemolung as well.

He said ALung is ramping up manufacturing, but that its inventory is limited because the device is in clinical trials. The Hemolung has been approved for use in Europe since 2013, and Mr. DeComo said some inventory could be shifted depending on which hospitals have need.

“This isn’t a cure, but it’s another tool in the toolbox,” he said, noting that the company isn’t charging for the device currently. “We want to do our part to help.”

Advertise with us

William Federspiel of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine designed the Hemolung. It is similar to an extracorporeal membrane oxygenation machine, which removes carbon dioxide and oxygenates a patient’s blood outside the body. ECMO devices have been endorsed for use on severely ill patients at hospitals around the state, including those in the Allegheny Health Network and UPMC health systems, according to an April 1 news release.

“Because [the Hemolung is] less invasive, it can be brought in earlier,” Mr. Federspiel said. “The hope would be that there would be some patients that would be kept off the ventilator altogether.”

The U.S. Food and Drug Administration has also granted emergency-use approval to the Spirio Wave, an automated resuscitator device designed by a consortium of New York City tech firms and inspired by an earlier design from the Massachusetts Institute for Technology. The low-cost device is easier to manufacture than traditional ventilators and began shipping to New York City hospitals last week.

Authorized for use on April 20, the Spiro Wave was the first ventilator device to receive emergency approval from the FDA, which has been receiving requests for emergency authorization since March.

Jeremy Reynolds: jreynolds@post-gazette.com or 412-263-1634; twitter: @Reynolds_PG. Mr. Reynolds' work at the Post-Gazette is supported by a grant from the San Francisco Conservatory of Music, Getty Foundation and Rubin Institute.

Advertise with us

This story was originally published with images that are no longer available.